20241015-太平洋-医药行业周报_诺华布西珠单抗新适应症在华申报上市_3页_375kb

China Pacific Securities Research Report Summary

Report Title: 医药行业周报
Date: October 15, 2024
Overall Rating: Neutral

Market Performance

• Pharmaceutical sector experienced a -231% price change in October, outperforming the CSI 300 index by 0.35 points (up 0.35% relative to CSI 300).
• Sector ranking in Shenzhen Index 31 was 19th, indicating mixed sentiment.
  • Leaders: Blood products (-0.85%), Pharmaceutical Circulation (-1.19%), Medical Equipment (-4.00%).
  • Laggers: Vaccines (-3.42%), R&D services (-3.10%).

Key Industry News

• Novartis's brolucizumab submitted for second marketing approval in China, targeting additional indications.
• New mechanism: Brolucizumab (molecular weight 26kDa) offers strong efficacy with minimal systemic side effects.

Company Updates

1. Jinyao Pharmaceutical: Passed bioequivalence evaluation for Lincomycin Hydrochloride Injection.
2. Lizu Group: Injection of Leuprolate Acetate Approval passed.
3. Hainuo Pharma: Entered Phase 3 trial for eribulin mesylate in ER+/HER2- breast cancer.
4. Huadong Healthcare: Initiated trial for HDP-101 targeting BCMA-positive hematologic malignancies.

Analyst Ratings

• Industry Rating: Neutral (expected returns between -5% and 5% relative to CSI 300).
• Key Companies:
  • Jinyao Pharmaceutical: Unrated.
  • Lizu Group: Unrated.
  • Hainuo Pharma: Unrated.
  • Huadong Healthcare: Unrated.

Key Risks

• Unmet expectations in new drug research or policy shifts.
• Heightened competition may challenge market share.

Research Analyst Views

Analysts highlight:

1. Market pricing dynamics may shift, potentially supporting valuation growth.
2. Regulatory developments for new therapies like brolucizumab hold promise for sector stability.

Contact

• Analysts: Zhou Yu, Zhang Wei
• Emails: Analyst registration codes provided.